Skip to main content

Table 6 Concordance indexes for resected pancreatic cancer in training and validation cohorts and in sensitivity analyses for the training US cohort

From: Development and validation of a prognostic model to predict the prognosis of patients who underwent chemotherapy and resection of pancreatic adenocarcinoma: a large international population-based cohort study

Model modification/subgroup

Concordance index

95% confidence interval

Training cohort

 The US, our nomogram

0.60

0.59–0.61

 The US, model based on both T and N stages

0.56

0.56–0.57

Validation cohorts

 Belgium, our nomogram

0.58

0.55–0.60

 Belgium, model based on both T and N stages

0.54

0.52–0.56

 The Netherlands, our nomogram

0.62

0.59–0.65

 The Netherlands, model based on both T and N stages

0.56

0.54–0.59

 Slovenia, our nomogram

0.58

0.51–0.65

 Slovenia, model based on both T and N stages

0.52

0.47–0.57

 Norway, our nomogram

0.63

0.55–0.71

 Norway, model based on both T and N stages

0.61

0.54–0.68

Sensitivity analyses for the training US cohort

 Replacement

  Age group in place of continuous age

0.59

0.59–0.60

  Metastatic lymph node number in place of N stage

0.60

0.59–0.61

  Lymph node ratio in place of N stage

0.61

0.61–0.62

  The 8th version of T stage in place of the original stage

0.61

0.60–0.61

  The 8th version of N stage in place of the original stage

0.60

0.59–0.61

  The 8th version of T & N stages in place of the original stages

0.61

0.60–0.62

 Addition

  Harvested lymph node added

0.60

0.60–0.61

  Tumor size added

0.61

0.60–0.61

  Harvested lymph node & tumor size added

0.61

0.60–0.62

 Subgroup

  Diagnosis after 2009

0.60

0.59–0.61

  White ethnicity

0.60

0.59–0.61

  Pancreas head

0.60

0.59–0.61

  Pancreas body & tail

0.61

0.59–0.63

  1. Concordance indexes in sensitivity analyses greater than that for the overall nomogram in the US are highlighted in italics